Precision Biosciences Inc (NASDAQ: DTIL)

Precision Biosciences Inc is a clinical stage gene editing company that develops in vivo therapeutic candidates using its proprietary ARCUS nuclease platform. The company focuses on creating permanent genetic treatments for serious unmet medical needs, including infectious diseases such as hepatitis B and genetic disorders like Duchenne muscular dystrophy. Its ARCUS technology enables precise DNA editing through a compact, single‑component enzyme that does not require guide RNA.

Precision Biosciences generates revenue primarily through licensing and collaboration agreements with biopharma partners. These arrangements provide upfront payments, milestone payments upon achievement of development or regulatory goals, and royalties on net sales of any resulting products. The company also receives payments from its exclusive license with Duke University and may earn income from future product sales once its therapies reach commercialization.

Within the gene editing sector, Precision Biosciences competes with established players such as CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Beam Therapeutics, Prime Medicine, Tune Therapeutics and Verve Therapeutics. Its competitive edge lies in the ARCUS platform’s unique staggered cut, small molecular size that fits within AAV vectors, and the absence of a required guide RNA, which together aim to improve delivery efficiency and editing precision. These characteristics are intended to differentiate its product candidates and support a stronger safety and efficacy profile versus existing technologies.

The company’s therapeutic programs target patients with chronic hepatitis B, Duchenne muscular dystrophy, mitochondrial disease, and rare genetic disorders such as ornithine transcarbamylase deficiency. In addition, Precision Biosciences collaborates with partners including Caribou Biosciences, TG Therapeutics, Imugene, Novartis and iECURE, who develop or commercialize products based on its ARCUS technology. These collaborations extend the company’s reach to broader patient populations and therapeutic areas.